# Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients

> **NCT06513949** · PHASE2 · RECRUITING · sponsor: **Implicit Bioscience** · enrollment: 56 (estimated)

## Conditions studied

- Acute Respiratory Distress Syndrome
- Adult Respiratory Distress Syndrome
- Acute Lung Injury
- Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

## Interventions

- **BIOLOGICAL:** Atibuclimab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06513949
- **Lead sponsor:** Implicit Bioscience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-15
- **Primary completion:** 2027-09
- **Final completion:** 2027-12
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2025-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06513949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06513949, "Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06513949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*